XM does not provide services to residents of the United States of America.
N
N

Novartis


News

US court finds ‘robust’ anti-fraud safeguards in Novartis settlement

US court finds ‘robust’ anti-fraud safeguards in Novartis settlement By Mike Scarcella July 26 (Reuters) - After thousands of improper claims were detected in a $30 million settlement with Novartis, a U.S. judge in Manhattan charged with reviewing the process said there were “robust” safeguards in place to ward off fraudulent distributions.
N

Health Rounds: Researchers discover key to the placebo effect in the brain

Health Rounds: Researchers discover key to the placebo effect in the brain Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here . By Nancy Lapid July 25 (Reuters) - Hello Health Rounds Readers! Today we highlight three early experimental findings: a fascinating discovery that may help explain the placebo effect, which causes people to respond to fake drugs, and two discoveries that
N

Dren Bio To Collaborate With Novartis To Develop Novel Targeted Myeloid Engagers For Cancer

BRIEF-Dren Bio To Collaborate With Novartis To Develop Novel Targeted Myeloid Engagers For Cancer July 24 (Reuters) - Novartis AG NOVN.S : DREN BIO ANNOUNCES STRATEGIC COLLABORATION WITH NOVARTIS TO DEVELOP NOVEL TARGETED MYELOID ENGAGERS FOR CANCER DREN BIO, INC. : ELIGIBLE TO RECEIVE UP TO $2.85 BILLION IN ADDITIONAL CASH PAYMENTS DREN BIO : TO G
N

Pharma aims to deliver personalized cancer therapies more quickly

FOCUS-Pharma aims to deliver personalized cancer therapies more quickly By Michael Erman NEW YORK, July 24 (Reuters) - Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they try to deliver them sooner in a patient's disease course.
G
N

Drug giants eye China for deals despite growing Sino-US tensions

ANALYSIS-Drug giants eye China for deals despite growing Sino-US tensions Bristol Myers Squibb, Sanofi looking at China M&A -employees AstraZeneca, Novartis have done China deals this year Political risks are a consideration -analysts By Andrew Silver and Kane Wu SHANGHAI/HONG KONG, July 23 (Reuters) - Some of the biggest global drugmakers, undeterred by mounting Sino-U.S.
A
N
S

Novartis AG reports results for the quarter ended in June - Earnings Summary

Novartis AG reports results for the quarter ended in June - Earnings Summary Novartis AG NVS.N reported quarterly adjusted earnings of $1.97​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.83. The mean expectation of eight analysts for the quarter was for earnings of $1.89 per share.
N

Novartis AG reports results for the quarter ended in June - Earnings Summary

Novartis AG reports results for the quarter ended in June - Earnings Summary Novartis AG NOVN.S reported quarterly adjusted earnings of $1.97​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.83. The mean expectation of ten analysts for the quarter was for earnings of $1.87 per share.
N

Tech seeking a floor after selloff

CORRECTED-LIVE MARKETS-Tech seeking a floor after selloff Corrects para 2 to "up" instead of "down" Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com TECH SEEKING A FLOOR AFTER SELLOFF European shares were expected to steady at the open on Thursday after three days of losses, as a sharp rotation move out of high-flying Big Tech stocks looked set for a breather.
N
N
V
A
E
F
U
G

Novartis CFO: Launch Of Cosentyx In Hidradenitis Suppurativa Going Beyond Our Expectations

BRIEF-Novartis CFO: Launch Of Cosentyx In Hidradenitis Suppurativa Going Beyond Our Expectations July 18 (Reuters) - Novartis AG NOVN.S : NOVARTIS CFO SAYS LAUNCH OF COSENTYX TO TREAT HIDRADENITIS SUPPURATIVA GOING BEYOND OUR EXPECTATIONS Further company coverage: NOVN.S
N

Novartis lifts profit forecast for second time on Cosentyx, Entresto

CORRECTED-UPDATE 2-Novartis lifts profit forecast for second time on Cosentyx, Entresto Corrects to $800 million, not billion, in paragraph 6 By Ludwig Burger FRANKFURT, July 18 (Reuters) - Swiss drugmaker Novartis NOVN.S raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto and arthritis drug Cosentyx .
N

Novartis raises 2024 profit guidance for second time

Novartis raises 2024 profit guidance for second time FRANKFURT, July 18 (Reuters) - Swiss drugmaker Novartis NOVN.S raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions of drugs including heart failure treatment Entresto and Kesimpta for multiple sclerosis. It said in a statement that full-year adjusted operating income is expected to grow by a "mid- to high teens" percentage, where it had previously seen a "low double-digit to mid-teens" percentag
N

Swiss stocks - Factors to watch on July 18

Swiss stocks - Factors to watch on July 18 ZURICH/GDANSK, July 18(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ABB ABBN.S The company reported a Q2 revenue of USD 8.24 billion NOVARTIS NOVN.S The company raised its guidance for its core operating income, expecting growth of mid- to high teens. VAT Group VACN.S The company says its H1 EBITDA is up, at CHF 135 million ROCHE ROG.S The company's Vabysmo study met all primary endpoints SFS Group SFSN.S The gr
A
N
R
S

Novartis AG <NVS.N> expected to post earnings of $1.89 a share - Earnings Preview

Novartis AG expected to post earnings of $1.89 a share - Earnings Preview Novartis AG NVS.N , NVS is expected to show a fall in quarterly revenue when it reports results on July 18 for the period ending June 30 2024 The Basel Basel-stadt-based company is expected to report a 9.2% decrease in revenue to $12.375 billion from $13.62 billion a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
N

Novartis AG <NOVN.S> expected to post earnings of $1.87 a share - Earnings Preview

Novartis AG expected to post earnings of $1.87 a share - Earnings Preview Novartis AG NOVN.S is expected to show a fall in quarterly revenue when it reports results on July 18 for the period ending June 30 2024 The Basel Basel-stadt-based company is expected to report a 9.2% decrease in revenue to $12.362 billion from $13.62 billion a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
N

Law firm Milberg skirts sanctions over fake claims in credit card fees case

Law firm Milberg skirts sanctions over fake claims in credit card fees case By Mike Scarcella July 15 (Reuters) - A law firm that said it unknowingly submitted fake claims as part of a $5.6 billion antitrust settlement with Visa and Mastercard will escape sanctions for now, a federal magistrate judge has ruled. U.S. Magistrate Judge Joseph Marutollo in Brooklyn said on Saturday that punishing plaintiffs law firm Milberg Coleman Bryson Phillips Grossman was “unnecessary at this time” after th
N
V

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds Unilever July 15 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO.HE : The Finnis
B
B
B
B
C
I
M
N
T
T
U
V
B
U

China c.bank seen holding medium-term lending rate steady Monday

RPT-China c.bank seen holding medium-term lending rate steady Monday Repeats story from Friday with no changes to text SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed.
B
N

China c.bank seen holding medium-term lending rate steady Monday

RPT-China c.bank seen holding medium-term lending rate steady Monday Repeats story from Friday with no changes to text SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed.
B
N

China c.bank seen holding medium-term lending rate steady Monday

China c.bank seen holding medium-term lending rate steady Monday SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed. While the economy continues to sputter, a weak Chinese currency has remained the key constraint limiting Beijing's monetary easing efforts, as that could further widen the yield gap with oth
B
N

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds details on fresh job cuts July 9 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO
B
B
B
B
C
I
M
N
T
T
U
V
B
U



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.